Study · Animal study (in vivo) · mouse · 2022

1 result

A long-acting C-natriuretic peptide for achondroplasia.

Schneider EL, Carreras CW, Reid R, Ashley GW, Santi DV

Proceedings of the National Academy of Sciences of the United States of America18 Jul 2022Cited by 10 (Europe PMC)

PMID35858423PMCIDPMC9335275DOI10.1073/pnas.2201067119PepBankPUB-35858423

Read at source PubMedAsk about this study

Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mice, daily vosoritide produced growth comparable to or below that produced by both microsphere CNP analog preparations.
In plain wordsIn mice, daily vosoritide produced growth comparable to or below growth with both microsphere CNP analog preparations.
Peptide
Vosoritide
Outcome
Direction not reportedGrowth
Study
mousen: not reported in source
Comparator
Microsphere [Gln6,14]CNP-38 conjugates
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Both preparations increased growth of mice comparable to or exceeding that produced by daily vosoritide.
Report a problemFND-3585842301

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.